Pfizer and WAVE Collaborate to Develop Metabolic Therapies
By Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 5 (Table of Contents)
Published: 28 May-2016
DOI: 10.3833/pdr.v2016.i5.2161 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal that will bolster its pipeline of early stage assets in metabolic diseases, Pfizer has entered into a drug development and collaboration deal potentially worth up to US$911 M with WAVE Life Sciences to develop novel drugs on nucleic acid-based therapies to treat the underlying causes of various metabolic diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS